Abstract
BackgroundSkin cutaneous melanoma (SKCM) is one of most aggressive type of cancers worldwide. Serglycin (SRGN) is an intracellular proteoglycan that playing an important role in various tumors. However, its effect on immune infiltrates and whether it associates with survival of SKCM and SKCM-metastasis patients has not been explored.MethodsWe evaluated SRGN expression via the databases of Oncomine, Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA). The influence of SRGN expression on survival of SKCM and SKCM-metastasis patients was analyzed using TIMER database. Furthermore, the correlations between SRGN expression and immune infiltrates or gene marker sets of immune infiltrates were also analyzed via TIMER database.ResultsWe found that the expression of SRGN in SKCM and SKCM-metastasis tissues was significantly increased compared to the normal skin tissues (P < 0.001). Interestingly, it was showed that lower level of SRGN expression and lower immune infiltrates of B cell, CD8+ T cell, Neutrophil, and Dendritic cell were correlated with poor survival rate of SKCM and SKCM-metastasis patients (P < 0.001) but not SKCM primary patients. We also demonstrated that SRGN expression was positively associated with the immune infiltrates and diverse immune marker sets in SKCM and SKCM-metastasis.ConclusionsOur findings indicated that SRGN was associated with the survival of SKCM and SKCM-metastasis patients. SRGN may be a new immune therapy target for treating SKCM and SKCM-metastasis.
Highlights
Skin cutaneous melanoma (SKCM) is one of most aggressive type of cancers worldwide
Increased expression of SRGN in SKCM and SKCMmetastasis tissues To better understand the role of SRGN in SKCM, we compared the expression of SRGN between SKCM (461samples) and normal (558samples) tissues in Gene Expression Profiling Interactive Analysis (GEPIA) database
We found that the expression of SRGN was further increased in SKCM metastasis tissues (Fig. 1b) which indicates that SRGN may play a key role in the progression of SKCM
Summary
Skin cutaneous melanoma (SKCM) is one of most aggressive type of cancers worldwide. Its effect on immune infiltrates and whether it associates with survival of SKCM and SKCM-metastasis patients has not been explored. Skin cutaneous melanoma (SKCM) is a major public health problem worldwide. The mortality of SKCM patients is still increasing. Numerous studies have shown that the dysfunction of immune system plays a key role in the progression of SKCM [4, 5]. It has been demonstrated that tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in SKCM patients [6]. Selitsky et al demonstrated that B cells have important predictive role in SKCM [5]. It is still necessary to find novel immune-related therapeutic targets in SKCM
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
